Kit Simpson to Drug Costs
This is a "connection" page, showing publications Kit Simpson has written about Drug Costs.
Connection Strength
0.316
-
Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya. Value Health. 2011 Dec; 14(8):1048-54.
Score: 0.093
-
Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study. Adv Ther. 2009 Feb; 26(2):185-93.
Score: 0.077
-
A new side of sarcoidosis: medication and hospitalization use in a privately insured patient population. Sarcoidosis Vasc Diffuse Lung Dis. 2019; 36(2):124-129.
Score: 0.039
-
A model for estimating the impact of changes in children's vaccines. Am J Public Health. 1995 Dec; 85(12):1666-72.
Score: 0.031
-
Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/microliters in 5 European countries. Pharmacoeconomics. 1994 Dec; 6(6):553-62.
Score: 0.029
-
Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model. Clin Drug Investig. 2009; 29(10):635-46.
Score: 0.019
-
A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease. Clin Drug Investig. 2008; 28(5):291-303.
Score: 0.018
-
Impact of zidovudine-based triple combination therapy on an AIDS drug assistance program. J Acquir Immune Defic Syndr. 2000 Apr 01; 23(4):302-13.
Score: 0.010